Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW’s Drug Distribution Guidelines Issued for Enforcement in April
January 26, 2018
- MHLW Reiterates Caution over Tagrisso Use after Opdivo Treatment
January 26, 2018
- IPRP to Hold First Meeting in June in Japan, May Take up Harmonization of Regulations on Regenerative Medicine Products
January 26, 2018
- Chuikyo Enters Final Review of FY2018 Fee Schedule Revision; Recommendation Due Out Feb. 7
January 25, 2018
- MHLW to Launch New Project to Strengthen Generic Drug Use in Around 10 “Priority Prefectures” Aiming at 80% Volume Share Target
January 25, 2018
- Japan Govt to Halt R&D Tax Break for Small Spender Companies: PM Abe
January 24, 2018
- Eligibility for Conditional Early Approval “Will Not Be Restricted to Orphan Drugs”: MHLW
January 24, 2018
- Japan’s 1st Herceptin Biosimilar Likely to Be OK’ed by March for Gastric Cancer
January 23, 2018
- Shionogi’s Sakigake-Designated Flu Med Up for MHLW Panel Review on Feb. 2, Early Listing Possible?
January 23, 2018
- Cooperation from Govt, Insurers to Meet 80% Generic Target, Control of Long-Term Prescriptions Requested: Chuikyo Public Hearings
January 22, 2018
- MHLW OKs Dupixent, Tecentriq, Lynparza, and More
January 22, 2018
- PMDA to Promote Simplification of Documentation Required in Applications, Acceptance of Documents in Electronic Form
January 19, 2018
- Chuikyo OKs New Drug Pricing Rules for FY2018 Reform
January 18, 2018
- Huge Seller Price Slash to Hit Nexium/Takecab; Rituxan, 8 Other Brands to Face Market Expansion Re-Pricing
January 18, 2018
- Chuikyo OKs Special Re-Pricing for FY2018 Drug Price Revision, Here’s the List of Products
January 17, 2018
- MHLW Health Policy Chief Wants Pricing Reform to Prod Drug Makers’ Overseas Expansions
January 17, 2018
- Chuikyo Plans for FY2018 Fee Schedule Revision Now Up for Public Comments
January 15, 2018
- Novo’s Semaglutide Up for MHLW Panel Review Jan. 26 after Approval Hold
January 15, 2018
- MHLW Orders Label Revisions for Abilify, 4 Other APIs
January 12, 2018
- Streamlining Regulations of Pharmaceutical Affairs to Be “a Top Priority” in 2018: MHLW Pharma Bureau Chief
January 12, 2018
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…